Pharmaceutical partners invest $6M in Eloxx to advance therapy for Duchenne MD | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Pharmaceutical partners invest $6M in Eloxx to advance therapy for Duchenne MD


Eloxx Pharmaceuticals received a $6 million investment from industry partners to advance a novel therapy for genetic diseases caused by nonsense mutations, including Duchenne muscular dystrophy (DMD), raising the total round of financing to $30 million.

The investment will be used to advance the development of ELX-02, the company’s lead development translation read-through inducing drug (TRID). Read-through therapy is a strategy followed in the treatment of genetic diseases caused by nonsense mutations to increase translation (protein production) and restore activity of the mutated proteins.

https://www.duchennexchange.org/wp-content/uploads/2017/07/Eloxx-to-Advance.jpg

rareRelated